AgomAb Therapeutics NV American Depositary Shares (AGMB) Stock
Fundamentals
Recent news

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
AGMB

Agomab Therapeutics files for US IPO
Agomab Therapeutics files for US IPO
AGMB
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 2 articles
published over the past 14 days
Latest news

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
AGMB

Agomab Therapeutics files for US IPO
Agomab Therapeutics files for US IPO
AGMB
About AgomAb Therapeutics NV American Depositary Shares
The company is a clinical-stage biopharmaceutical organization focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial emphasis on chronic fibrotic conditions that have significant unmet medical needs. Its product candidates are designed to target established biological pathways and employ validated therapeutic modalities, with the goal of enhancing efficacy while minimizing systemic toxicities and addressing the limitations of prior treatment approaches.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Tim Knotnerus MSc, Ph.D. | CEO & Executive Director | 1983 |
| Mr. Paolo Michieli Ph.D. | Founder, Senior Advisor & Member of Scientific Advisory Board | — |
| Mr. Pierre Kemula B.Sc. | Chief Financial Officer | 1974 |
| Sofie Van Gijsel | Vice President of Investor Relations | — |
| Ms. Ellen Lefever | General Counsel | 1985 |
| Dr. Philippe Wiesel M.D. | Chief Medical Officer | 1967 |
| Dr. Paul Van Der Horst Ph.D. | Chief Business Officer | 1988 |
| Dr. Andrea Sáez Borderías Ph.D. | Chief Development Officer | 1982 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +9.4 | -35.3 | -7.9 | +0.5 | +13.5 | +8.4 | -2.6 | -22.4 |



